| Toby Ferguson |
Toby Ferguson is currently working as the Chief Medical Officer at Voyager Therapeutics, Inc. He previously worked as the VP & Head-Neuromuscular Development Unit at Biogen, Inc. Dr. Ferguson holds a doctorate degree from the University of Florida College of Medicine and an undergraduate degree from the University of Florida. |
| Jacquelyn Fahey Sandell |
Jacquelyn Fahey Sandell is currently the Secretary & Chief Legal Officer at Jounce Therapeutics, Inc. and the Chief Legal Officer at Voyager Therapeutics, Inc. She previously worked as an Associate General Counsel at Millennium Pharmaceuticals, Inc., Vice President & General Counsel at Vericel Corp., and Senior Corporate Counsel at Genzyme Corp. Ms. Sandell received her undergraduate degree from Duke University and her graduate degree from Boston University School of Law. |
| Michelle Quinn Smith |
Michelle Quinn Smith is currently the Director at Horse Hugs For Heroes and the Chief Human Resources Officer at Voyager Therapeutics, Inc. She previously worked as the Global Head-Human Resources at Sanofi, Inc. Ms. Smith completed her undergraduate degree at Chestnut Hill College. |
| Michael J. Higgins |
Michael J. Higgins is currently the Chief Executive Officer & Director at KinDex Pharmaceuticals, Inc. He is also the Chairman at Voyager Therapeutics, Inc. and Pulmatrix, Inc. Additionally, he serves as a Director at Sea Pharmaceuticals LLC, Madauder Therapeutics, Inc., and CAMP4 Therapeutics Corp. He is an Independent Director at Cyclerion Therapeutics, Inc. and Nocion Therapeutics, Inc. Furthermore, he holds positions as a Director at Morgan Stanley Private Equity Access Fund II LP and Private Equity Access Fund II. In the past, Mr. Higgins worked as a Director at Pulmatrix Operating Co., Inc. and held positions at Microbia, Inc., Genocea Biosciences, Inc., Ruthigen, Inc., Genzyme Corp., Ironwood Pharmaceuticals, Inc., Procept, Inc., and Boston Business Journal. Mr. Higgins completed his undergraduate studies at Cornell University and earned an MBA from the Tuck School of Business at Dartmouth. |
| Robin Swartz |
Robin Swartz is currently the Chief Operating Officer at Voyager Therapeutics, Inc. Prior to this role, Mr. Swartz held positions as a Director at Sanofi-Aventis, Inc. and as a Vice President-Patient & Product Services at Genzyme Corp. Mr. Swartz completed their undergraduate degree at Kenyon College. |
| Todd Carter |
Todd Carter is currently the Chief Scientific Officer at Voyager Therapeutics, Inc. He started this position in 2022. Dr. Carter has a doctorate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Texas A&M University. |
| Beth Shafer |
Beth Shafer is currently the Chief Business Officer at Voyager Therapeutics, Inc. She holds a doctorate degree from the University of California. |
| Nathan Dean Jorgensen |
Nathan Dean Jorgensen's current job is as the Chief Financial & Accounting Officer at Voyager Therapeutics, Inc. Dr. Jorgensen's former jobs include being a Director at OncoResponse, Inc., an Associate Research Analyst at Stifel, Nicolaus & Co., Inc. from 2012 to 2013, and a Senior Research Analyst at Calamos Advisors LLC. He also served as the Chief Financial Officer at Vor Biopharma, Inc. from 2020 to 2024. Dr. Jorgensen's education includes an MBA from Cornell University in 2010, an undergraduate degree from St. John's University in 1999, and a doctorate from the University of Minnesota in 2007. |
| Glenn F. Pierce |
Glenn F. Pierce's current job(s) include being the Director at the World Federation of Hemophilia since 2015, an Independent Director at Voyager Therapeutics, Inc. since 2017, and the Chief Medical Officer & Senior Vice President at Bioverativ Therapeutics, Inc. since 2009. He is also a Member of the American Society of Hematology, The International Society On Thrombosis & Haemostasis, and the Hemostasis & Thrombosis Research Society. Dr. Pierce's former job(s) include being an Independent Director at Global Blood Therapeutics, Inc. from 2016 to 2022. He was also a Principal at Amgen, Inc., Vice President-Research & Clinical Development at Avigen, Inc., Chief Medical Officer & SVP-Global Medical Affairs at Biogen, Inc. from 2009 to 2014, Vice President-Applied Research Hematology at Bayer Healthcare LLC, Vice President-PreClinical Development at Prizm Pharmaceuticals, Inc. from 1994 to 1998, and Vice President-Therapeutic Product Development at Selective Genetics, Inc. from 1998 to 2002. He also served as the President of the National Hemophilia Foundation and was the Chief Medical Officer at Ambys Medicines, Inc. from 2018 to 2020. Dr. Pierce's education includes a graduate degree from Washington University in St. Louis and undergraduate and doctorate degrees from Case Western Reserve University. |
| Trista Morrison |
Trista Morrison is currently the Director at Network of Tyrosinemia Advocates, Inc. and the Chief of Staff & SVP Corporate Affairs at Voyager Therapeutics, Inc. She previously worked as the Director-Corporate Communications at Ironwood Pharmaceuticals, Inc., the Head-Media Relations at Gemin X Pharmaceuticals US, Inc., and the Chief Communications Officer at Saniona AB. Ms. Morrison completed her undergraduate degree at Tulane University (Louisiana). |
| Peter P. Pfreundschuh |
Peter P. Pfreundschuh is currently the Director at Gitbasic LLC and the Director at Speratus Therapeutics, Inc. He is also the Chief Financial & Accounting Officer at Voyager Therapeutics, Inc. since 2022. Previously, he worked as the Executive Director-Business Development at AstraZeneca Pharmaceuticals LP from 2007 to 2008. He also served as the Director at Reproductive Medicine Associates of New Jersey and Principal at American Standard Cos., Inc. From 2013 to 2016, he held the position of Chief Financial Officer & Executive VP-Finance at Immunomedics, Inc. Prior to that, he worked as a Principal at Johnson & Johnson from 1999 to 2007. He also has experience as an Auditor at Ernst & Young LLP and as the Chief Financial Officer & Treasurer at 3-Dimensional Pharmaceuticals, Inc. From 2008 to 2013, he served as the Chief Financial Officer at CircuLite, Inc. He was the Chief Financial Officer at Sucampo Pharmaceuticals LLC from 2017 to 2018. Additionally, he worked as a Principal at Alimenterics, Inc. and as the Chief Financial & Compliance Officer, Secretary at UroGen Pharma Ltd. from 2018 to 2020. From 2020 to 2022, he held the position of Chief Financial Officer at Frequency Therapeutics, Inc. Mr. Pfreundschuh obtained an MBA from Rider University in 2002 and an undergraduate degree from Rutgers Business School in 1991. |
| Alfred W. Sandrock |
Alfred W. Sandrock is currently the President, Chief Executive Officer & Director at Voyager Therapeutics, Inc. He is also the Chairman at PhRMA Foundation and a Director at Verge Analytics, Inc., Disarm Therapeutics, Inc., Atalanta Therapeutics, Inc., and Transition Bio, Inc. Additionally, he is a Member of the American Academy of Neurology, a Professor at Harvard Medical School, and an Advisor at Longwood Fund Management LLC. In his former positions, Dr. Sandrock served as an Independent Director at Neurocrine Biosciences, Inc. from 2015 to 2020. He was also a Director at FORUM Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc. Furthermore, he held the position of Head-Research & Development at Biogen, Inc. from 2020 to 2021 and served as the Chief Medical Officer at Biogen Idec, Inc. (North Carolina). Dr. Sandrock obtained his doctorate degree from Harvard University in 1988. He completed his undergraduate studies at Stanford University in 1979. He also holds a doctorate degree from Harvard Medical School. |
| George A. Scangos |
George A. Scangos is the founder of Rezo Therapeutics, Inc. (founded in 2022) and holds the title of Chairman. He is currently the Vice Chairman at Fondation Santé since 2011 and an Independent Director at Agilent Technologies, Inc. since 2011. He is also a Director at Biomedical Sciences Careers Program, Inc., Octave Bioscience, Inc., Vir Biotechnology, Inc., and ARCH Venture Partners LLC. Additionally, he serves as a Trustee at Cornell University, an Analyst at IS. Yatirim Menkul Degerler. AS (Broker), and a Member-National Board of Visitors at UC Davis School of Medicine. He is a Trustee at Life Science Cares, Inc. Dr. Scangos's former positions include being the Chief Executive Officer & Director at Biogen, Inc. from 2010 to 2017. He was also the Chief Executive Officer at Biogen Idec New Ventures, Inc. and Biogen Idec, Inc. (North Carolina) from 2010 to 2017. He served as the Chairman at Anadys Pharmaceuticals, Inc. from 2003 to 2010 and the Chairman at Pharmaceutical Research & Manufacturers of America from 2016 to 2017. He was the Chairman at California Healthcare Institute and a Director at Onyx Pharmaceuticals, Inc. from 2000 to 2005. He served as a Director at Exelixis, Inc. from 1996 to 2020 and a Non-Executive Director at Entelos, Inc. from 1997 to 2010. He was also a Director at Global Alliance for TB Drug Development, Taconic Biosciences GmbH, Symphony Evolution, Inc., Baybio Institute, Decibel Therapeutics, Inc., Bayer Corp., Bayer, Inc., and Bayer Biotechnology. Dr. Scangos's education includes an undergraduate degree from Cornell University and a doctorate degree from the University of Massachusetts. |
| James Arthur Geraghty |
James Arthur Geraghty is currently the Chairman at Catalent JNP, Inc., Pieris Pharmaceuticals, Inc., Orchard Therapeutics (Europe) Ltd., OMass Therapeutics Ltd., Bio Ventures for Global Health, Therapeutic Human Polyclonals, Inc., Voyager Therapeutics, Inc., CANbridge Life Sciences Ltd., Fulcrum Therapeutics, Inc., and CANbridge Pharmaceuticals Inc. He previously served as the Chairman, President & Chief Executive Officer at rEVO Biologics, Inc. and the Chairman at Catalent JNP, Inc. from 2015 to 2018. He was also the Chairman at Orchard Therapeutics Plc from 2018 to 2024. Additionally, he held positions as a Director at Idera Pharmaceuticals, Inc., ImmuneXcite, Inc., and bluebird bio, Inc. He was a Director at Aceragen, Inc. from 2013 to 2023 and served as the Senior Vice President at Third Rock Ventures LLC from 2013 to 2016. Prior to that, he was the Senior Vice President-International Development at Genzyme Corp. from 2007 to 2011 and the President at Genzyme Europe BV from 1998 to 2000. He also worked as the Senior VP-Strategy & Business Development at Sanofi SA from 2012 to 2013. Mr. Geraghty holds a graduate degree from the University of Pennsylvania, an undergraduate degree from Georgetown University, and a graduate degree from Yale Law School. |
| Catherine J. Mackey |
Catherine J. Mackey is currently the Chief Executive Officer at Cyprus Therapeutics, Inc., an Independent Director at Avid Bioservices, Inc., and a Director at Rady Children's Hospital & Health Center of San Diego, BIOCOM, San Diego Athena, Voyager Therapeutics, Inc., IDEAYA Biosciences, Inc., and Rady Children's Institute for Genomic Medicine. She has previously served as the Chairman at Cour Pharmaceuticals Development Co., Inc., a Director at Sequenom, Inc., YM BioSciences, Inc., Viventia Biotech, Inc., and Genelux Corp. She was also an Independent Non-Executive Director at GW Pharmaceuticals Ltd. from 2017 to 2021. Additionally, she has held positions as a Director at Ajinomoto Althea, Inc., CONNECT, Project Concern International, and Infinant Health, Inc. Dr. Mackey's former roles also include being a Vice President at DEKALB Genetics Corp. from 1990 to 1998 and a Senior VP-Worldwide Research & Development at Pfizer Inc. from 1999 to 2010. She holds an undergraduate degree and a doctorate from Cornell University. |
| Steven E. Hyman |
Steven E. Hyman is the founder of Emugen Therapeutics LLC. He currently holds multiple positions including Chairman at The Dana Foundation, Director at Janssen Pharmaceuticals, Inc., Director-Stanley Center Psychiatric Research at Massachusetts Institute of Technology, Director at Charles H. Revson Foundation, Inc., Director-Stanley Center for Psychiatric Research at The Broad Institute, Inc., Independent Director at Voyager Therapeutics, Inc., Independent Director at Q-State Biosciences, Inc., Independent Director at Cyclerion Therapeutics, Inc., Member of the National Academy of Medicine (United States), Member of The National Research Council, President of the American College of Neuropsychopharmacology, and Member of the National Academy of Sciences. He previously served as the Director of the National Institute of Mental Health from 1996 to 2001 and as a Professor at Harvard University from 2001 to 2011. He also held positions as President of the Society For Neuroscience, Strategic Advisor at Access BridgeGap Ventures, and President of the International Neuroethics Society. Dr. Hyman received a doctorate degree from Harvard Medical School and an undergraduate degree from Yale College. |
| Grace E. Colón |
Dr. Grace E. Colón is a Chairman at Bloom Science, Inc., an Independent Director at Voyager Therapeutics, Inc., an Executive Chairman at ProterixBio, Inc., a Member at Latino Corporate Directors Association and a Member at Women Corporate Directors. She is on the Board of Directors at Voyager Therapeutics, Inc., Biotechnology Innovation Organization, MIT Corp. (United States) and Massachusetts Institute of Technology. Dr. Colón was previously employed as an Independent Director by CareDx, Inc., a Partner by New Science Ventures LLC, a Co-Founder by Pyranose Biotherapeutics, a President, Chief Executive Officer & Director by InCarda Therapeutics, Inc., a Head-Clinical Operations by Gilead Sciences /Oncology Operations/, a President-Industrial Products Division & SVP by Intrexon Corp., a Chief Operating Officer by International Genomics Consortium, a Vice President-Corporate Planning by Affymetrix, Inc., and an Engagement Manager by McKinsey & Co., Inc. She also served on the board at Paradigm Diagnostics, Inc., Cocoon Biotech, Inc. and PerceptiMed, Inc. She received her undergraduate degree from the University of Pennsylvania and a doctorate degree from the University of Massachusetts. |
| Nancy J. Vitale |
Nancy J. Vitale is the founder of Partners For Wellbeing. She currently holds the position of Director at Make-A-Wish Foundation of America. Additionally, she is an Independent Director at Voyager Therapeutics, Inc. since 2020 and the Chief People Officer at Omada Health, Inc. since 2022. Previously, she worked as the Senior Vice President-Human Resources at Genentech, Inc. and as a Member at Roche Group. Ms. Vitale completed her undergraduate degree at the University of Michigan and holds an MBA from Goizueta Business School-Emory. |
